The Booroola mutation in sheep is associated with an alteration of the bone morphogenetic protein receptor-IB functionality

J Endocrinol. 2003 Jun;177(3):435-44. doi: 10.1677/joe.0.1770435.

Abstract

The hyperprolificacy phenotype of Booroola ewes is due to the presence of the FecB(B) allele at the FecB locus, recently identified as a single amino acid substitution (Q249R) in the bone morphogenetic protein (BMP) type-IB receptor (BMPR1B), and is associated with a more precocious differentiation of ovarian granulosa cells (GCs). To evaluate the consequences of the Booroola mutation on BMPR1B functions, the action of ligands of the transforming growth factor-beta (TGFbeta)/BMP family that act through (growth and differentiation factor-5, BMP-4) or independently of (activin A, TGFbeta-1) BMPR1B were studied on primary cultures of GCs from homozygous FecB(+) and FecB(B) ewes. All the tested TGFbeta/BMP family ligands inhibited progesterone secretion by FecB(+) GCs. Those inhibitory effects were lower for GCs from preovulatory (5-7 mm diameter) than from small antral follicles (1-3 mm diameter). The presence of the Booroola mutation was associated with a 3- to 4-fold (P<0.001) decreased responsiveness of GCs from FecB(B) compared with FecB(+) small follicles to the action of BMPR1B ligands. In contrast, TGFbeta-1 and activin A had similar inhibitory effects on progesterone secretion by GCs from FecB(+) and FecB(B) small follicles. No difference between genotypes was observed with GCs from preovulatory follicles. In transfection experiments with HEK-293 cells, co-expression of FecB(+) BMPR1B and BMPR2 resulted in a 2.6-fold (P<0.01) induction of the activity of a BMP-specific luciferase reporter construct by BMP-4. Interestingly, no response to BMP-4 was observed when cells were transfected with the FecB(B) form of the BMPR1B receptor. Overall, these data strongly suggest that the Q249R mutation is associated with a specific alteration of BMPR1B signaling in hyperprolific Booroola ewes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activins / pharmacology
  • Analysis of Variance
  • Animals
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Protein Receptors, Type I
  • Bone Morphogenetic Proteins / pharmacology
  • Cell Division / drug effects
  • Cell Line
  • Cells, Cultured
  • Female
  • Genotype
  • Granulosa Cells / metabolism*
  • Growth Differentiation Factor 5
  • Humans
  • Inhibin-beta Subunits / pharmacology
  • Progesterone / metabolism
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism*
  • Receptors, Growth Factor / genetics
  • Receptors, Growth Factor / metabolism*
  • Sheep / genetics*
  • Sheep / metabolism*
  • Signal Transduction / physiology*
  • Transfection
  • Transforming Growth Factor beta / pharmacology

Substances

  • BMP4 protein, human
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins
  • GDF5 protein, human
  • Growth Differentiation Factor 5
  • Receptors, Growth Factor
  • Transforming Growth Factor beta
  • activin A
  • Activins
  • Progesterone
  • Inhibin-beta Subunits
  • Protein Serine-Threonine Kinases
  • BMPR1B protein, human
  • Bone Morphogenetic Protein Receptors, Type I